Asymmetric dimethylarginine plasma concentrations and L-arginine/asymmetric dimethylarginine ratio in patients with slow coronary flow

Coronary Artery Disease

Volumn 18, Issue 7, 2007, Pages 545-551

  Selcuk, Mehmet Timur ^a,b   Selcuk, Hatice ^a   Temizhan, Ahmet ^a   Maden, Orhan ^a   Ulupinar, Hakan ^a   Baysal, Erkan ^a   Ozeke, Ozcan ^a   Sasmaz, Ali ^a  

^a TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

^b KC Goksupark Havuzluevler   (Turkey)

Author keywords

Asymmetric dimethylarginine; Endothelial dysfunction; Slow coronary flow

Indexed keywords

ARGININE; N(G),N(G) DIMETHYLARGININE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; ENDOTHELIAL DYSFUNCTION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SLOW CORONARY FLOW PHENOMENON; THROMBOLYSIS IN MYOCARDIAL INFARCTION FRAME COUNT;

ADULT; AGED; ARGININE; BLOOD FLOW VELOCITY; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORONARY ANGIOGRAPHY; CORONARY CIRCULATION; EXERCISE TEST; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; NITRIC OXIDE; SENSITIVITY AND SPECIFICITY; THROMBOLYTIC THERAPY;

EID: 35048900189     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e3282eff1c6     Document Type: Article

References (31)

1. Tambe AA, Demany MA, Zimmerman HA, Mascarenhas E. Angina pectoris and slow flow velocity of dye in coronary arteries - a new angiographic finding. Am Heart J 1972; 84:66-71.
2. Goel PK, Gupta SK, Agarwal A, Kapoor A. Slow coronary flow: a distinct angiographic subgroup in syndrome X. Angiology 2001; 52:507-514.
3. Mangieri E, Macchiarelli G, Ciavolella M, Barilla F, Avella A, Martinotti A, et al. Slow coronary flow: clinical and histopathological features in patients with otherwise normal epicardial coronary arteries. Cathet Cardiovasc Diagn 1996; 37:375-381.
4. Cin VG, Pekdemir H, Camsar A, Cicek D, Akkus MN, Parmaksyz T, et al. Diffuse intimal thickening of coronary arteries in slow coronary flow. Jpn Heart J 2003; 44:907-919.
5. Sezgin AT, Sigirci A, Barutcu I, Topal E, Sezgin N, Ozdemir R, et al. Vascular endothelial function in patients with slow coronary flow. Coron Artery Dis 2003; 14:155-161.
6. Riza Erbay A, Turhan H, Yasar AS, Ayaz S, Sahin O, Senen K, et al. Elevated level of plasma homocysteine in patients with slow coronary flow. Int J Cardiol 2005; 102:419-423.
7. Landmesser U, Drexler H. The clinical significance of endothelial dysfunction. Curr Opin Cardiol 2005; 20:547-551.
8. Leiper J, Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res 1999; 43:542-548.
9. Cooke JP. Asymmetrical dimethylarginine: the Uber marker? Circulation 2004; 109:1813-1818.
10. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339:572-575.
11. Curgunlu A, Uzun H, Bavunoglu I, Karter Y, Genc H, Vehid S. Increased circulating concentrations of asymmetric dimethylarginine (ADMA) in white coat hypertension. J Hum Hypertens 2005; 19:629-633.
12. Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002; 106:987-992.
13. Fard A, Tuck CH, Donis JA, Sciacca R, Di Tullio MR, Wu HD, et al. Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol 2000; 20:2039-2044.
14. Eid HM, Arnesen H, Hjerkinn EM, Lyberg T, Seljeflot I. Relationship between obesity, smoking, and the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine. Metabolism 2004; 53:1574-1579.
15. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999; 99:1141-1146.
16. Boger RH. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res 2003; 59:824-833.
17. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98:1842-1847.
18. Bode-Boger SM, Boger RH, Kienke S, Junker W, Frolich JC. Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. Biochem Biophys Res Commun 1996; 219:598-603.
19. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
20. Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B Jr, Marble SJ, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 1996; 93:879-888.
21. Kurtoglu N, Akcay A, Dindar I. Usefulness of oral dipyridamole therapy for angiographic slow coronary artery flow. Am J Cardiol 2001; 87:777-779, A8.
22. Pekdemir H, Polat G, Cin VG, Camsari A, Cicek D, Akkus MN, et al. Elevated plasma endothelin-1 levels in coronary sinus during rapid right atrial pacing in patients with slow coronary flow. Int J Cardiol 2004; 97:35-41.
23. Vallance P. Importance of asymmetrical dimethylarginine in cardiovascular risk. Lancet 2001; 358:2096-2097.
24. Camsarl A, Pekdemir H, Cicek D, Polat G, Akkus MN, Doven O, et al. Endothelin-1 and nitric oxide concentrations and their response to exercise in patients with slow coronary flow. Circ J 2003; 67:1022-1028.
25. Barutcu I, Sezgin AT, Sezgin N, Gullu H, Esen AM, Topal E, et al. Elevated plasma homocysteine level in slow coronary flow. Int J Cardiol 2005; 101:143-145.
26. Stuhlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 2001; 104:2569-2575.
27. Beltrame JF, Limaye SB, Horowitz JD. The coronary slow flow phenomenon - a new coronary microvascular disorder. Cardiology 2002; 97:197-202.
28. Cesar LA, Ramires JA, Serrano Junior CV, Meneghetti JC, Antonelli RH, da-Luz PL, et al. Slow coronary run-off in patients with angina pectoris: clinical significance and thallium-201 scintigraphic study. Braz J Med Biol Res 1996; 29:605-613.
29. Delles C, Schneider MP, John S, Gekle M, Schmieder RE. Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N(G), N(G)-dimethylarginine in human essential hypertension. Am J Hypertens 2002; 15:590-593.
30. Stuhlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002; 287:1420-1426.
31. Mintz GS, Painter JA, Pichard AD, Kent KM, Satler LF, Popma JJ, et al. Atherosclerosis in angiographically 'normal' coronary artery reference segments: an intravascular ultrasound study with clinical correlations. J Am Coll Cardiol 1995; 25:1479-1485.